Evidence and availability map · 7 November 2026
| Example | Status | Check with |
|---|---|---|
| Wegovy / Mounjaro | Medicines with authorised indications; assessment and prescribing follow product information. | EMA / CIMA |
| Retatrutide / CagriSema | Phase 3 programmes; a trial does not establish availability in Spain. | ClinicalTrials.gov |
| Foundayo (not a peptide) | Positive CHMP opinion; check Commission decision and national launch. | EMA |
| BPC-157 / CJC-1295 | Muscle or injury claims lack sufficient clinical evidence and confirmed authorisation for those uses. | FDA / CIMA |
The word peptide is not an approval
A peptide is a chain of amino acids. Its chemical structure alone does not determine usefulness, safety or permission to sell. Some peptide medicines passed clinical trials and manufacturing controls; other molecules remain in basic research. “Research use only” or an overseas seller does not turn a vial into an authorised Spanish medicine. For a named product, begin with the European Medicines Agency record and Spain’s AEMPS CIMA register.
What a doctor can assess now
Wegovy (semaglutide) and Mounjaro (tirzepatide) have European product records describing indications, contraindications and efficacy and safety data for selected patients. They are not interchangeable with every “weight-loss peptide” advertised online. Exact indication and formulation matter. A clinician considers BMI, history, other medicines and preferences. A prescription medicine is dispensed through an authorised pharmacy, rather than bought from a Spanish website like a supplement.
Names in the research headlines
Retatrutide, developed by Eli Lilly, has been studied in the Phase 3 TRIUMPH programme, including TRIUMPH-1. CagriSema, Novo Nordisk’s cagrilintide and semaglutide combination, has been studied in the Phase 3 REDEFINE-1 trial. These are advanced programmes, but trial registration or results news is not authorisation or evidence of pharmacy stock in Spain. The public trial record helps verify sponsor, participants, criteria, outcome measures and update date. Check each product’s current regulatory status before saying it is available.
A GLP-1 tablet that is not a peptide
Eli Lilly’s Foundayo (orforglipron) shows why words matter: it acts on the GLP-1 receptor but is a non-peptide small molecule, not a peptide. EMA’s CHMP issued a positive opinion on 15 October 2026. On the EMA page consulted 7 November 2026, a European Commission decision was still described as a subsequent step, so we do not claim it is sold in Spain. Positive opinion, EU authorisation, national launch and stock at an individual pharmacy are different milestones.
What about muscle and injury peptides?
BPC-157 is promoted for injuries; CJC-1295 and ipamorelin for muscle gain. The FDA has highlighted safety and quality uncertainty for some preparations. A small retrospective knee study involving 16 people cannot establish tissue repair. A registered muscle-injury trial is an open scientific question, not an available cure. Athletes also need to check anti-doping rules. A reasonable hope is that controlled trials establish whether any candidate provides benefits that outweigh risks, in which patients and at what dose.
How to follow progress without falling for hype
Ask for five facts: exact name, sponsor, trial phase, measured clinical outcome and regulatory status in Spain. A weight-loss percentage in a press release does not by itself describe withdrawals, adverse effects or how comparable two trials are. For muscle, strength and function matter; for injury, safe return to activity. Costa will update these guides when a regulatory source or published trial changes the picture. Follow the linked series to separate new evidence from advertising, or speak to a doctor about treatments available now.
How a laboratory molecule reaches a pharmacy
A result in cells or animals may justify studying a candidate, but does not yet answer whether it helps people. Early trials study doses and safety signals; later trials compare clinical outcomes in more participants. Review of efficacy, risks, manufacturing and quality follows. European authorisation, the product information and actual availability in Spanish pharmacies are separate milestones.
That is why this guide distinguishes “approved”, “in a trial” and “promoted without sufficient evidence”. A candidate’s category may change. Before asking for a product, check the EMA medicines database and Spain’s CIMA register using the exact name and formulation.
Which advances are worth following?
For obesity, researchers are testing combinations and new molecules that might improve outcomes, tolerability or convenience. For sports injuries, repair mechanisms are being investigated, but a biological change is not the same as safe return to sport. For muscle, a candidate should demonstrate strength and function rather than just hormone changes. These are research possibilities, not promises about what will become prescribable or curable.
Two trials cannot be ranked by a percentage alone: participants, duration, dose and handling of withdrawals may all differ. Look for participant numbers, comparison groups, absolute effects, adverse events and how long benefits lasted. A trial record and published paper give more context than a headline.
A practical checklist for following the field
- Identify whether the product is a peptide, another molecule or simply a brand name.
- Check the indication: weight management, diabetes, another disease or no approved use.
- Ask whether the news comes from a completed trial, a press release or a regulatory review.
- Separate authorisation from actual national launch and stock in an individual pharmacy.
We will update these guides when published results or verifiable regulatory decisions change the picture. A consultation today should be based on available options and the patient’s needs, not an imagined launch date.
Frequently asked questions
Which peptides are approved for weight management?
There are authorised peptide medicines, including Wegovy and Mounjaro, for specific indications; check the exact formulation and product record.
Are retatrutide or CagriSema on sale in Spain?
A Phase 3 trial alone does not establish that. Check current authorisation and launch before assuming availability.
Is BPC-157 approved for sports injury repair?
We found no Spanish authorisation for that indication; published human evidence is insufficient.
Does a positive EMA opinion mean my pharmacy stocks it?
No. A formal decision, national launch and local stock may still follow.